Oppenheimer & CO Inc Incyte Corp Transaction History

Oppenheimer & CO Inc

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 07, 2023	SELL	$57.77 - $65.93 $352,628 - $402,436	-6,104 Reduced 40.51%	8,965 $517,000
Q2 2023 Aug 02, 2023	BUY	$60.95 - $75.51 $918,455 - $1.14 Million	15,069 New	15,069 $938,000
Q1 2022 May 12, 2022	SELL	$66.02 - $79.71 $317,226 - $383,006	-4,805 Closed	0 $0
Q4 2021 Feb 02, 2022	SELL	$63.34 - $74.11 $13,871 - $16,230	-219 Reduced 4.36%	4,805 $353,000
Q3 2021 Nov 12, 2021	SELL	$68.67 - $84.02 $86,386 - $105,697	-1,258 Reduced 20.03%	5,024 $345,000
Q2 2021 Aug 03, 2021	BUY	$79.87 - $87.53 $263,730 - $289,024	3,302 Added 110.81%	6,282 $529,000
Q1 2021 May 10, 2021	SELL	$76.02 - $100.5 $2,660 - $3,517	-35 Reduced 1.16%	2,980 $242,000
Q4 2020 Feb 11, 2021	BUY	$80.74 - $97.7 $19,216 - $23,252	238 Added 8.57%	3,015 $262,000
Q3 2020 Nov 13, 2020	BUY	$85.07 - $109.69 $2,296 - $2,961	27 Added 0.98%	2,777 $249,000
Q1 2020 May 08, 2020	BUY	$63.18 - $85.97 $173,745 - $236,417	2,750 New	2,750 $201,000
Q3 2019 Oct 31, 2019	SELL	$72.82 - $86.52 $234,771 - $278,940	-3,224 Closed	0 $0
Q2 2019 Aug 09, 2019	SELL	$73.52 - $88.7 $5,514 - $6,652	-75 Reduced 2.27%	3,224 $274,000
Q1 2019 Apr 24, 2019	SELL	$63.56 - $88.17 $9,406 - $13,049	-148 Reduced 4.29%	3,299 $284,000
Q4 2018 Jan 29, 2019	BUY	$58.5 - $69.94 $201,649 - $241,083	3,447 New	3,447 $220,000

644

186M

714K

557K

Ticker INCY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 222,431,008
Market Cap $16.6B
Description
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as ...

Get notified when there are updates to the investment portfolio of Oppenheimer & CO Inc, based on Form 13F filings with the SEC.

Stay updated on Oppenheimer & CO Inc with notifications on news.